Abstracts Archive - Page 912 of 1683 - ATC Abstracts

2018 American Transplant Congress
Advancement in Perioperative Outcomes of Living Donors in Pure Laparoscopic Right Hepatectomy
Y. Choi, H. Han, Y. Yoon, J. Cho, B. Lee.
Department of Surgery, Seoul National University, College of Medicine, Seongnam, Republic of Korea.
Background In the early period, laparoscopic liver resection was applied in limited cases, but now the number of cases and its application is rapidly increasing.…
2018 American Transplant Congress
Water-Jet Dissection for Donor Hepatectomy during Living Donor Liver Transplantation
K. Gotoh,¹ H. Eguchi,¹ Y. Iwagami,¹ D. Yamada,¹ T. Asaoka,¹ T. Noda,¹ K. Kawamoto,¹ S. Kobayashi,¹ K. Umeshita,² Y. Doki,¹ M. Mori.¹
¹Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan; ²Health Science, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Background The most important issue in living donor liver transplantation (LDLT) is donor safety. Although donor hepatectomy has evolved technically over the years, it is…
2018 American Transplant Congress
Complications and QoL after Living Donor Hepatectomy: Analysis of 176 Cases at a Single Center
S. Chinnakotla, V. Kirchner, S. Mongin, D. Berglund, O. Serrano, T. Pruett.
Department of Surgery, University of Minnesota, Minneapolis.
Background: Living liver donation is one of the most selfless and humane acts a person can perform. Few single-center reports have been published specifically evaluating…
2018 American Transplant Congress
Living Liver Donation is Safe in Donors Heterozygous for an alpha-1 Antitrypsin Gene Mutation
T. Bittermann,¹ L. Wood,² P. Abt,² A. Shaked,² K. Olthoff,² D. Goldberg.^1,3
¹Division of Gastroenterology, University of Pennsylvania, Philadelphia, PA; ²Division of Transplant Surgery, University of Pennsylvania, Philadelphia, PA; ³Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA.
Patients homozygous for an alpha-1 antitrypsin mutation, particularly the Pi*ZZ phenotype, develop cirrhosis and pulmonary emphysema. Those with a heterozygous phenotype are thought to have…
2018 American Transplant Congress
Impact of Donor Age on Outcomes after Living Donor Liver Transplantation
K. Hayashi,¹ K. Gotoh,¹ H. Eguchi,¹ Y. Iwagami,¹ D. Yamada,¹ T. Asaoka,¹ T. Noda,¹ K. Kawamoto,¹ S. Kobayashi,¹ K. Umeshita,² Y. Doki,¹ M. Mori.¹
¹Dept of Gastroenterological Sugery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan; ²Division of Health Science, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Background: Liver transplantation (LT) is a curative treatment for decompensated cirrhosis and fulminant hepatitis. Although not a few patients received LT with marginal donor livers…
2018 American Transplant Congress
Impact of Preserved Collateral Veins on Small-for-Size Grafts in Living Donor Liver Transplantation
B-.G. Na, E. Lee, S. Kim, S. Park.
Center for Liver Cancer, National Cancer Center Research Institute, Goyang, Republic of Korea.
Purpose: Graft size is a critical issue in living donor liver transplantation (LDLT). We hypothesized that too much portal flow could possibly be diverted into…
2018 American Transplant Congress
Renal and Bone Safety in Post Liver Transplant Patients with Chronic Kidney Disease Receiving Tenofovir Alafenamide for HBV Prophylaxis
E. Gane,¹ B. George,¹ S. Munn,¹ H. Wang,² V. Suri,² A. Gaggar.²
¹Auckland City Hospital, Auckland, New Zealand; ²Gilead Sciences, Foster City, CA.
Background and Aims: Chronic Hepatitis B (CHB) remains a leading indication for orthotopic liver transplantation (OLT) globally. Common complications following OLT include renal dysfunction secondary…
2018 American Transplant Congress
A Comparison of the Discard Rate in Hepatitis C Deceased Liver Donors between Two Eras, 2008-2013 and 2014-2017. A Single Organ Procurement Organization Experience
M. Nazzal,¹ G. Marklin,² O. Okoye,¹ Y. Kim,¹ R. Ouseph.¹
¹Abdominal Transplant, Saint Louis University, Saint Louis, MO; ²Mid America Transplant, Saint Louis, MO.
With the introduction of new hepatitis C medications in 2014 , there is a growing concern for an increase in the discard rate of hepatitis…
2018 American Transplant Congress
Benefit of Anti-Hepatitis B Immunoglobulin(HBIG) Monotherapy Compared to HBIG Combined with Entecavir in Long Term Renal Function
J. Lee,¹ D. Kim,¹ J. Lee,² S. Kim,³ H. Lee,⁴ S. Song,⁵ J. Lee,¹ M. Ju,¹ G. Choi,¹ D. Joo,¹ J. Choi,¹ S. Kim,¹ Y. Jung.¹
¹Department of Surgery, Yonsei University of College of Medicine, Seoul, Republic of Korea; ²Department of Surgery, CHA Bundang Medical Center, Seongnam, Republic of Korea; ³Department of Surgery, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea; ⁴Department of Surgery, Ilsan Hospital, Ilsan, Republic of Korea; ⁵Department of Surgery, Ehwa Wonmen Hospital, Seoul, Republic of Korea.
Background: To reduce the HBV reinfection after liver transplantation, anti-hepatitis B immunoglobulin (HBIG) alone or combination with antiviral nucleotide analogues are usually used regimen. However,…
2018 American Transplant Congress
Efficacy of Generic Sofosbuvir and Branded Daclatasvir Compared to Sofosbuvir and Ledipasvir Combination in the Treatment of Genotype 4 Hepatitis C Virus
H. Joharji, A. Al-Jedai, D. Alkortas, A. Ajlan, E. Devol, M. Ahmed, F. Aba Al-Khail, H. El-Siesy, M. Al-Sebayel, H. Al-Ashgar, M. Al-Quaiz, W. Alhomodi, A. Aloubal, A. Almohishir.
King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
Genotype 4 HCV is the most common genotype in Saudi Arabia and the Middle East. Management of genotype 4 HCV has shifted to interferon free…